Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below 200-Day Moving Average – What’s Next?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $13.66 and traded as low as $13.40. Enanta Pharmaceuticals shares last traded at $13.83, with a volume of 141,517 shares changing hands.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ENTA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th. Rodman & Renshaw started coverage on Enanta Pharmaceuticals in a research report on Thursday, March 26th. They issued a “buy” rating and a $20.00 price objective for the company. Wall Street Zen raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.29.

Enanta Pharmaceuticals Stock Performance

The company has a market cap of $405.64 million, a PE ratio of -5.39 and a beta of 1.01. The stock has a 50 day moving average of $13.57 and a 200-day moving average of $13.66.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%.The business had revenue of $17.16 million during the quarter, compared to analyst estimates of $17.03 million. Equities research analysts forecast that Enanta Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently modified their holdings of ENTA. Janus Henderson Group PLC boosted its holdings in shares of Enanta Pharmaceuticals by 1.5% during the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after purchasing an additional 54,396 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 30.6% during the 4th quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock worth $43,719,000 after purchasing an additional 650,000 shares during the last quarter. Krensavage Asset Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 30.8% during the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after purchasing an additional 651,946 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 50.2% during the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after purchasing an additional 449,945 shares during the last quarter. Finally, Spruce Street Capital LP lifted its holdings in Enanta Pharmaceuticals by 139.3% in the first quarter. Spruce Street Capital LP now owns 932,598 shares of the biotechnology company’s stock valued at $11,779,000 after acquiring an additional 542,911 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.